Gastrointestinal Neuroendocrine Tumors Market Set to Surge by 2034 Amidst Advancements in Treatment Options | DelveInsight
The gastrointestinal neuroendocrine tumors market is experiencing steady growth driven by increasing disease prevalence, improved diagnostic capabilities, and rising awareness of targeted therapies. Additionally, growing investment in research and development, along with the launch of emerging therapies such as ITM-11 (n.c.a. 177Lu-edotreotide) (ITM Solucin GmbH), CAM2029 (Camurus), RYZ101 (Actinium-225 DOTATATE) (Bristol Myers Squibb/RayzeBio), and others, […]